Best Injectable Peptides for Anti-Aging

Key takeaways

• No injectable peptide has been shown to slow aging. The honest ranking sorts injectables by what they have done in human trials and by whether a US pharmacy can legally dispense them.
• Top of the list is a drug, not a "longevity peptide": semaglutide cut the combined rate of cardiovascular death, heart attack and stroke from 8.0% to 6.5% in 17,604 adults with heart disease and overweight, average age 62.
• Tesamorelin (visceral fat down about 15% in six months in adults with HIV) and sermorelin (growth hormone and IGF-1 up) have real trials and a legal prescription path, but no aging outcome. NAD+ and glutathione can be compounded and have no outcome evidence as injections.
• BPC-157, TB-500, epitalon, MOTS-c, injectable GHK-Cu, CJC-1295, ipamorelin, thymosin alpha-1 and kisspeptin-10 cannot be legally compounded in October 2026, whatever a clinic page says.
• Growth hormone sets the ceiling for every peptide that raises it: in healthy older adults it moved about 2 kg from fat to lean mass and brought more swelling, joint pain, carpal tunnel syndrome and diabetes.

The best injectable peptides for anti-aging, judged by evidence, are not the ones sold under that name. No injectable has been shown to slow aging. Three have human trials and a legal US prescription path: semaglutide, with heart-outcome data in older adults; tesamorelin, which reduces visceral fat; and sermorelin, which raises growth hormone. NAD+ and glutathione can be compounded but have no outcome evidence as injections, and the rest of the usual list cannot be legally compounded at all. This page ranks them; the parent guide, best peptides for women over 40 and 50, covers weight, skin, sleep and energy by goal, and its sibling covers peptides for weight loss in women.

The ranking

What the top three actually do

Semaglutide. SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more but no diabetes; 4,872 were women. Over about 40 months, semaglutide 2.4 mg a week lowered the combined rate of cardiovascular death, heart attack and stroke by 20% (hazard ratio 0.80), and 16.6% stopped for adverse events against 8.2% on placebo (Lincoff 2023). It is the only hard-outcome trial any injectable peptide has in older adults, and it applies to people with heart disease and excess weight, not to healthy adults. See the longevity ranking.

Tesamorelin. The only GHRH analog with a current FDA approval. In 412 adults with HIV and treatment-related abdominal fat, 86% of them men, 2 mg a day for 26 weeks reduced visceral fat by 15.2% while it rose 5.0% on placebo, lowered triglycerides and raised IGF-1 by 81%; more people withdrew for adverse events on the drug (Falutz 2007). Outside HIV there is one 12-month trial: in 60 abdominally obese adults with low growth hormone output, tesamorelin reduced visceral fat by 35 square centimeters against placebo and improved triglycerides, C-reactive protein and carotid wall thickness without changing glucose (Makimura 2012). A real visceral-fat drug, not a youth drug. See the tesamorelin profile.

Sermorelin. A copy of the first 29 amino acids of growth hormone-releasing hormone, legally compounded because it was once an approved drug. The longest trial in older adults used a closely related analog nightly for 16 weeks in 10 women and 9 men aged 55 to 71: growth hormone and IGF-1 rose in both sexes and skin thickness increased, but lean mass, insulin sensitivity, well-being and libido improved only in the men, and sleep did not change (Khorram 1997). See the sermorelin profile and sermorelin for women.

The ceiling: growth hormone itself

Sermorelin, tesamorelin, CJC-1295 and ipamorelin all work by raising growth hormone, so growth hormone's own record caps what they can promise. In a systematic review of randomized trials in healthy adults with a mean age of 69, growth hormone reduced fat by 2.1 kg and increased lean mass by 2.1 kg without changing weight, bone density or most lipids, and raised the rates of soft-tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, with somewhat more new diabetes; the authors concluded it "cannot be recommended as an antiaging therapy" (Liu 2007). Distributing growth hormone for anti-aging is also a federal crime, which is why clinics sell secretagogues instead; see HGH peptides.

NAD+ and glutathione: legal, popular, unproven

NAD+ is a coenzyme, not a peptide. In a pilot study of a 6-hour intravenous infusion, plasma NAD+ and its breakdown products did not change for the first 2 hours: the infused NAD+ was "rapidly and completely removed from the plasma" (Grant 2019). No trial has tested NAD+ injections or drips against any outcome in healthy adults. See the NAD+ profile.

Glutathione is a tripeptide every cell makes. Where IV glutathione was tested in a randomized trial, in Parkinson's disease, 1,400 mg three times a week for 4 weeks produced no significant difference from placebo (Hauser 2009); the skin-lightening data are mostly for oral glutathione. FDA warned compounders about contaminated injectable glutathione in 2019 and again in August 2026; see the glutathione profile.

The ones no pharmacy may compound

• BPC-157, TB-500, epitalon and MOTS-c. FDA's advisory committee recommended them for the permitted list in July 2026 over its own reviewers' objections; until FDA completes rulemaking, no pharmacy may compound them.
• Injectable GHK-Cu, and the GLOW and KLOW blends built on it. Off FDA's safety-risk list since April 2026 but not permitted, with committee review due by February 2027; no human study of injected GHK-Cu for skin exists. See GHK-Cu injection versus topical.
• CJC-1295 and ipamorelin. Voted down by the committee in late 2024; see the profile.
• Thymosin alpha-1 and kisspeptin-10. Thymosin alpha-1 was voted down in December 2024; kisspeptin-10 is still on FDA's Category 2 safety-risk list (FDA categories 2026).
• SS-31 (elamipretide). Approved only for Barth syndrome, a rare inherited disease; there is no legitimate wellness supply.

Any of these sold online or by a clinic is a research vial; the full status table is in the legal tracker.

Doses and a units example

Sermorelin is the one most often mixed at home, and telehealth prescriptions (200 to 500 mcg nightly, per our sermorelin dosage chart) sit well below the trial doses. As arithmetic only: a 6 mg vial reconstituted with 3 mL of bacteriostatic water holds 2,000 mcg per mL, so 300 mcg is 0.15 mL, or 15 units on a U-100 insulin syringe. Check your own vial in the peptide calculator and the units converter, and see how to reconstitute peptides for technique.

Who should avoid them

• Growth hormone-raising peptides (sermorelin, tesamorelin): active or recent cancer, diabetic retinopathy or uncontrolled diabetes, pregnancy or breastfeeding, and known pituitary disease. IGF-1 and glucose should be measured before and during treatment.
• GLP-1 drugs: a personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy, and severe gastroparesis; see is tirzepatide safe.
• IV NAD+ and glutathione: anyone who cannot confirm the pharmacy and the grade of the ingredient.
• Women over 40: the tesamorelin trials were mostly men, and in the GHRH-analog trial the benefits went to men. Women who could still conceive need contraception with all of these.

How to get one legitimately

Ask three questions before paying: which named, state-licensed pharmacy fills it; on what legal basis the substance can be compounded; and what the clinician will measure to decide whether it works. Prices are in the cost guide, and providers are compared in the clinic directory.

Bottom line

There is no anti-aging injection, but there are injectables that treat real problems in older adults: semaglutide for weight and heart risk, tesamorelin for visceral fat, sermorelin for a measured growth hormone deficit. NAD+ and glutathione are legal and unproven. Everything else on the typical list is unproven and, in October 2026, has no legal pharmacy source.

Frequently asked questions

+−What is the best injectable peptide for anti-aging?

No injectable peptide has been shown to slow aging. If you mean the injectable with the strongest outcome evidence in older adults, it is semaglutide: in 17,604 adults with heart disease and overweight, average age 62, it cut the combined rate of cardiovascular death, heart attack and stroke from 8.0% to 6.5%. Tesamorelin reduces visceral fat and sermorelin raises growth hormone, and both can be legally prescribed, but neither has an aging outcome. Most injectables sold as anti-aging peptides cannot be legally compounded at all.

+−Are longevity peptides legitimate?

The compounds are real; the longevity claims are not supported. Epitalon, MOTS-c, BPC-157 and TB-500 have animal or cell data and no human trial of aging, and as of October 2026 no US pharmacy may compound them, although FDA's advisory committee recommended several in July 2026 and rulemaking is pending. Growth hormone itself, which CJC-1295 and ipamorelin are sold to raise, moved fat to lean mass in healthy older adults without changing bone density and with more side effects.

+−What are the negative side effects of peptide injections?

Each has its own. GLP-1 drugs cause nausea and other gut symptoms, and 16.6% of SELECT participants stopped semaglutide for adverse events against 8.2% on placebo. Growth hormone-raising peptides can cause injection-site reactions, fluid retention, joint pain and higher blood sugar. IV glutathione made from supplement-grade powder caused endotoxin reactions that led to FDA warnings. Research vials add unknown content and no label. Injection itself can cause bruising, infection and allergic reactions.

+−What does the NAD injection do?

It raises NAD+ briefly, and nobody has shown that it does more. In a pilot study of a 6-hour intravenous NAD+ infusion, plasma NAD+ did not rise for the first 2 hours because the body cleared it as fast as it arrived. No trial has tested NAD+ injections or drips against fatigue, cognition or any aging outcome in healthy adults. NAD+ is not a peptide; it is compounded under FDA's interim policy and costs $105 to $350 a month at home or $250 to $1,500 per clinic IV session.

+−Which is better, NAD or copper peptides?

Neither has outcome evidence as an injection. Injected NAD+ has a pharmacokinetic pilot and no clinical trial; injected copper peptide (GHK-Cu) has no human study at all and cannot be legally compounded in October 2026. As topicals, copper peptide has small cosmetic studies and NAD+ has none worth citing. For skin, sunscreen and a retinoid outperform both.

+−Can you inject peptides for skin tightening?

Clinics and research-vial sellers offer it, but no published human study has tested an injected peptide for skin appearance, and the peptides used (GHK-Cu, GLOW and KLOW blends) cannot be legally compounded in October 2026. In the one GHRH-analog trial that measured it, skin thickness on the hands and forearm increased in both sexes by caliper measurement, which is not the same as a visible result. Procedures and topical retinoids are the evidence-based routes.

+−Is peptide therapy Botox?

No. Botox is botulinum toxin, a protein injected into specific muscles to relax them and soften expression lines, and it is FDA-approved for that use. Peptide therapy usually means compounded peptides injected under the skin for systemic effects such as growth hormone release or weight loss. Topical 'Botox-like' peptides such as Argireline are cosmetics with small, mixed studies and are not substitutes.

Sources

1. StudyLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-32. (2023)
2. StudyFalutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70. (2007)
3. StudyMakimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:4769-79. (2012)
4. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
5. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
6. StudyGrant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019;11:257. (2019)
7. StudyHauser RA et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009;24:979-83. (2009)
8. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)